Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 4/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.98 |
| ▸ | P4HB | P07237 | 5/20 | 0.98 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.98 |
| ▸ | GAA | P10253 | 4/20 | 0.98 |
| ▸ | POLB | P06746 | 3/20 | 0.98 |
| ▸ | MAPT | P10636 | 3/20 | 0.98 |
| ▸ | CA12 | O43570 | 3/20 | 0.98 |
| ▸ | CA2 | P00918 | 3/20 | 0.98 |
| ▸ | CA4 | P22748 | 3/20 | 0.98 |
| ▸ | CA7 | P43166 | 3/20 | 0.98 |
| ▸ | ALPL | P05186 | 2/20 | 0.98 |
| ▸ | ALPI | P09923 | 2/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.98 |
| ▸ | KDM1A | O60341 | 1/20 | 0.98 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.98 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.98 |
| ▸ | PKM | P14618 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avicularin SCHEMBL1252098 | 1.00 | AKR1B1 (1.00) | AKR1B1L3MBTL1KDM4EP4HBEPHX2 | |
| Avicularin SCHEMBL30637540 | 1.00 | AKR1B1 (1.00) | AKR1B1L3MBTL1KDM4EP4HBEPHX2 | |
| Avicularin SCHEMBL29505880 | 1.00 | AKR1B1 (1.00) | AKR1B1L3MBTL1KDM4EP4HBEPHX2 | |
| Avicularin SCHEMBL119816 | 1.00 | AKR1B1 (1.00) | AKR1B1L3MBTL1KDM4EP4HBEPHX2 | |
| Avicularin SCHEMBL13182845 | 1.00 | AKR1B1 (1.00) | AKR1B1L3MBTL1KDM4EP4HBEPHX2 | |
| Avicularin SCHEMBL25174412 | 1.00 | AKR1B1 (1.00) | AKR1B1L3MBTL1KDM4EP4HBEPHX2 | |
| Avicularin SCHEMBL1626867 | 1.00 | AKR1B1 (1.00) | AKR1B1L3MBTL1KDM4EP4HBEPHX2 | |
| Avicularin SCHEMBL30185786 | 1.00 | AKR1B1 (1.00) | AKR1B1L3MBTL1KDM4EP4HBEPHX2 | |
| Avicularin SCHEMBL181203 | 1.00 | AKR1B1 (1.00) | AKR1B1L3MBTL1KDM4EP4HBEPHX2 | |
| Isoquercetin SCHEMBL12710506 | 0.99 | P4HB (1.00) | AKR1B1L3MBTL1KDM4EP4HBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 620 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3780974-B1 | GUAVA EXTRACT | PM INT AG (LU) | 2025-11-12 | — | — | EP | claimed |
| US-20240350574-A1 | PHENOLIC PHYTOCHEMICALS FOR BONE METASTASIS OF CANCER | NDSU RESEARCH FOUNDATION | 2024-10-24 | — | — | US | claimed |
| US-20240325484-A1 | COMPOSITION COMPRISING HORSE CHESTNUT EXTRACT | ANGIOLAB, INC. (KR) | 2024-10-03 | — | — | US | claimed |
| EP-4395802-A1 | COMPOSITION COMPRISING HORSE CHESTNUT EXTRACT | ANGIOLAB., INC. (KR) | 2024-07-10 | — | — | EP | claimed |
| CN-117860794-A | Processing method of mistletoe and quality detection method of processed product thereof | 山西中医药大学 | 2024-04-12 | — | — | CN | claimed |
| CN-113873429-B | Underground tunnel-oriented ridge regression two-dimensional positioning method and system | 国网江苏省电力有限公司电力科学研究院 | 2024-03-26 | — | — | CN | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| CN-116966195-A | Compound, composition and application thereof in preparation of medicines with effects of preventing and/or treating cardiomyopathy | 海南医学院第一附属医院 | 2023-10-31 | — | — | CN | claimed |
| CN-115969867-A | Application of avicularin in preparation of medicine/health-care product for preventing and treating osteoporosis | 张家港市中医医院 | 2023-04-18 | — | — | CN | claimed |
| CN-113552242-B | Method for constructing Chinese rose fingerprint, detection method and content determination method | 广东一方制药有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-20030105031-A1 | Methods for the treatment of skin disorders | QUIGLEY CORPORATION, THE | 2003-06-05 | — | — | US | claimed |
| US-20030105027-A1 | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury | QUIGLEY CORPORATION, THE | 2003-06-05 | — | — | US | claimed |
| WO-2003039452-A2 | NUTRITIONAL SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF RADIATION INJURY | THE QUIGLEY CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| US-6555573-B2 | Comprising a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor, antioxidant and carrier; side effect reduction; partial recovery of neurological function in some cases | THE QUIGLEY CORPORATION | 2003-04-29 | — | — | US | claimed |
| CN-1383381-A | Therpauetic agent of osteoporisis comprising active ingredient of quercetin derivatives | KOREA INST ORIENTAL MEDICINE (KR) | 2002-12-04 | — | — | CN | claimed |
| US-20020165207-A1 | Compositions and methods for the treatment of diabetic neuropathy | QUIGLEY CORPORATION, THE | 2002-11-07 | — | — | US | claimed |
| US-20020115618-A1 | Method and composition for the topical treatment of diabetic neuropathy | QUIGLEY CORPORATION, THE | 2002-08-22 | — | — | US | claimed |
| WO-2002049575-A2 | METHOD AND COMPOSITION FOR THE TREATMENT OF DIABETIC NEUROPATHY | THE QUIGLEY CORPORATION (US) | 2002-06-27 | — | — | WO | claimed |
| US-20020054924-A1 | Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor | LEAHY MARGARET M (US) | 2002-05-09 | — | — | US | claimed |
| WO-2001080870-A2 | COMPOSITIONS DERIVED FROM CRANBERRY AND GRAPEFRUIT AND THERAPEUTIC USES THEREFOR | OCEAN SPRAY CRANBERRIES, INC. (US) | 2001-11-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105027-A1 | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury | FOXO3, NQO1, FOXO1 | AKR1B1 834/4885L3MBTL1 4004/4885KDM4E 3889/4885 |
| US-20030105031-A1 | Methods for the treatment of skin disorders | TYR, CUTA, NFATC1 | AKR1B1 462/4885L3MBTL1 4806/4885KDM4E 871/4885 |
| US-20240325484-A1 | COMPOSITION COMPRISING HORSE CHESTNUT EXTRACT | PRUNE1, HDLBP, CROCC | AKR1B1 3109/4885L3MBTL1 4005/4885KDM4E 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.